The content of this report will be updated with the latest scenarios based on the global COVID-19 Pandemic
The Global DNA vaccines market is predicted to grow at a CAGR of 41.89%, generating $xx million by the end of the forecast period of 2018-2026. Factors like increasing investments for third-generation vaccines, increasing adoption in animal healthcare and potential application of these vaccines in identifying growing prevalence of diseases is influencing the market growth.
The Global DNA Vaccines Market is segmented on the basis of types, technologies, and applications. The types are further segmented into animal DNA vaccine and human DNA vaccine. The market technologies include plasmid DNA vaccines and Plasmid DNA delivery. The market finds its applications for veterinary as well as human diseases. At present, veterinary applications are leading the segment.
The Global DNA vaccines market covers the regions of North America, Asia-Pacific, Europe and rest of world. The North American market is expected to hold a dominant share by the end of the forecast period. The rising prevalence of incessant diseases in countries such as the US and Canada is fueling the market growth. The Asia-Pacific region is expected exhibit the fastest growth between 2018-2026, due to emerging interests in third-generation DNA vaccination, government support, and increasing conduction of clinical trials.
Eurogentec S.A, Madison Vaccines Incorporated (MVI), Sanofi, Inovio Pharmaceuticals Inc and Novartis Ag are the leading market players in the global market. The other key market companies include Astellas Pharma Inc, Dendreon Corporation, Eli Lilly And Company, Glaxosmithkline Inc, Merial Limited (Acquired By Boehringer Ingelheim), Merck & Co, Vgxi, Vical Incorporated, Xenetic Biosciences Inc and Zoetis Inc.